Daniela Chaparro-Reyes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniela Chaparro-Reyes has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Gloria Sanclemente
Group of Investigative Dermatology (GRID), Medical Research Institute, School of Medicine, University of Antioquia, Medellin, Colombia; Hospital Alma Mater de Antioquia (Formerly IPS Universitaria), Medellín, Colombia; Hospital San Vicente Fundacion, Medellin, Colombia
3 shared publications - Liliana Tamayo
Asociación Colombiana de Dermatología (ASOCOLDERMA) Universidad Pontificia Bolivariana; Grupo Clipso Enfermedades Inmunomediadas de Piel Medellín, Colombia
3 shared publications - Angela María Londoño-García
CES University Medellin Colombia
2 shared publications - Carolina Cortés Correa
Hospital Universitario de la Samaritana, Bogotá, Colombia
2 shared publications - Juan Raúl Castro-Ayarza
Dermatology Postgraduate Program, Faculty of Medicine, National University of Colombia, Bogota, Colombia
2 shared publications - Laura Charry
Pontificia Universidad Javeriana, Bogotá, Colombia
2 shared publications
Latest Publications
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 5742100
Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP‐1 Receptor Agonists and Tirzepatide
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and tirzepatide have moved rapidly from diabetes management into widespread obesity treatment, drawing growing interest in their dermatologic implications. Given the close relationship between obesity, insulin resistance, systemic inflammation, nutritional alterations, and cutaneous homeostasis, these agents may influence the skin through both beneficial and adverse mechanisms. Objective: To review and critically evaluate the current literature regarding the dermatologic effects of GLP‐1RAs and tirzepatide, with emphasis on differentiating direct pharmacologic effects, indirect weight loss–mediated effects via metabolic changes, and multifactorial and uncertain mechanisms. Methods: A focused narrative review was conducted in accordance with the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) using targeted searches in PubMed/MEDLINE, Scopus, and Embase through April 2026. Preference was given to systematic reviews, meta‐analyses, randomized clinical trials, multicenter observational studies, translational mechanistic research, and pharmacovigilance reports. Selected case reports were incorporated when considered clinically relevant. Findings were analyzed according to study quality, biological plausibility, consistency among different evidence sources, and applicability to dermatologic practice. Results: Among the potential beneficial dermatologic effects, psoriasis showed the most promising evidence, with meta‐analytic studies reporting reductions in Psoriasis Area and Severity Index scores and achievement of PASI 75 in a proportion of patients. Hidradenitis suppurativa also showed improvement in several observational studies, including reductions in disease activity, pain, and flare frequency, although the independent contribution of weight loss and metabolic improvement remains difficult to separate. Additionally, experimental data suggest possible benefits in wound repair through anti‐inflammatory and angiogenic modulation, but clinical evidence in dermatology is still scarce. Hair loss emerged as the most consistently reported adverse cutaneous event; pharmacovigilance analyses and pooled clinical trial data suggest an increased risk, most commonly compatible with telogen effluvium associated with rapid weight reduction and metabolic stress. Injection‐site reactions and mild hypersensitivity phenomena are relatively frequent but usually transient, whereas severe immune‐mediated reactions appear uncommon and are mainly supported by isolated reports. Publicly discussed entities such as “Ozempic face” and concerns about altered outcomes of cosmetic procedures currently exceed the strength of the available scientific evidence. Conclusions: GLP‐1RAs and tirzepatide should not be regarded primarily as dermatologic therapies; however, their cutaneous effects highlight the growing intersection between metabolic disease, systemic inflammation, nutritional status, and skin biology. Existing evidence suggests possible benefits in selected inflammatory dermatoses, a plausible association with appendageal adverse effects, and substantial overinterpretation of aesthetic complications in public discourse. Dermatologists should interpret these findings cautiously, avoiding both premature therapeutic enthusiasm and disproportionate safety concerns.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 5742100
Open AccessDermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP‐1 Receptor Agonists and Tirzepatide
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and tirzepatide have moved rapidly from diabetes management into widespread obesity treatment, drawing growing interest in their dermatologic implications. Given the close relationship between obesity, insulin resistance, systemic inflammation, nutritional alterations, and cutaneous homeostasis, these agents may influence the skin through both beneficial and adverse mechanisms. Objective: To review and critically evaluate the current literature regarding the dermatologic effects of GLP‐1RAs and tirzepatide, with emphasis on differentiating direct pharmacologic effects, indirect weight loss–mediated effects via metabolic changes, and multifactorial and uncertain mechanisms. Methods: A focused narrative review was conducted in accordance with the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) using targeted searches in PubMed/MEDLINE, Scopus, and Embase through April 2026. Preference was given to systematic reviews, meta‐analyses, randomized clinical trials, multicenter observational studies, translational mechanistic research, and pharmacovigilance reports. Selected case reports were incorporated when considered clinically relevant. Findings were analyzed according to study quality, biological plausibility, consistency among different evidence sources, and applicability to dermatologic practice. Results: Among the potential beneficial dermatologic effects, psoriasis showed the most promising evidence, with meta‐analytic studies reporting reductions in Psoriasis Area and Severity Index scores and achievement of PASI 75 in a proportion of patients. Hidradenitis suppurativa also showed improvement in several observational studies, including reductions in disease activity, pain, and flare frequency, although the independent contribution of weight loss and metabolic improvement remains difficult to separate. Additionally, experimental data suggest possible benefits in wound repair through anti‐inflammatory and angiogenic modulation, but clinical evidence in dermatology is still scarce. Hair loss emerged as the most consistently reported adverse cutaneous event; pharmacovigilance analyses and pooled clinical trial data suggest an increased risk, most commonly compatible with telogen effluvium associated with rapid weight reduction and metabolic stress. Injection‐site reactions and mild hypersensitivity phenomena are relatively frequent but usually transient, whereas severe immune‐mediated reactions appear uncommon and are mainly supported by isolated reports. Publicly discussed entities such as “Ozempic face” and concerns about altered outcomes of cosmetic procedures currently exceed the strength of the available scientific evidence. Conclusions: GLP‐1RAs and tirzepatide should not be regarded primarily as dermatologic therapies; however, their cutaneous effects highlight the growing intersection between metabolic disease, systemic inflammation, nutritional status, and skin biology. Existing evidence suggests possible benefits in selected inflammatory dermatoses, a plausible association with appendageal adverse effects, and substantial overinterpretation of aesthetic complications in public discourse. Dermatologists should interpret these findings cautiously, avoiding both premature therapeutic enthusiasm and disproportionate safety concerns.
- Open Access
- 15 November 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (6)
Satisfação do paciente como indicador de qualidade no atendimento dermatológico: estudo transversal em duas instituições terciárias com programas de residência
- 15 November 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (6)
Open AccessSatisfação do paciente como indicador de qualidade no atendimento dermatológico: estudo transversal em duas instituições terciárias com programas de residência
- Open Access
- 13 December 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Diagnóstico y tratamiento de la dermatitis atópica en Colombia. Actualización de la guía de práctica clínica
Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel altamente prevalente que afecta de manera negativa la calidad de vida de los pacientes y puede asociarse con comorbilidades sistémicas y afectación psicosocial. Se requiere la actualización de las guías de diagnóstico y tratamiento adecuado de la población y del contexto sanitario local. Objetivo: Esta actualización de la guía de práctica clínica (GPC), de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma), proporciona recomendaciones basadas en la evidencia para la evaluación y el manejo de la DA en Colombia, con un enfoque específico en tratamientos sistémicos, tópicos y terapias coadyuvantes, así como la gravedad y la gestión del riesgo. Estas recomendaciones están dirigidas a profesionales de la salud, tomadores de decisiones y pacientes. Métodos: Para desarrollar esta guía, se conformó un panel multidisciplinario de expertos y se llevó a cabo un proceso riguroso de revisión sistemática de la literatura para responder preguntas clínicas específicas. La certeza en la evidencia y la fuerza de las recomendaciones se evaluaron utilizando el enfoque GRADE (Grading of Recommendations Assessment, Development and Evaluation, por sus siglas en inglés). Resultados: El panel de expertos alcanzó consenso en once recomendaciones y nueve puntos de buena práctica para la atención de personas con DA. La revisión de la evidencia destaca la eficacia de crisaborol tópico, dupilumab, abrocitinib y upadacitinib en el manejo de la DA, con recomendaciones específicas para su uso en diferentes poblaciones. Se incluyen además recomendaciones para la descolonización de reservorios, la inmunoterapia con alérgenos y la restricción alimentaria, así como para la gestión del riesgo en el uso de terapias biológicas e inhibidores de las janocinasas (JAK, por sus siglas en inglés). Conclusiones: Esta guía proporciona recomendaciones actualizadas y basadas en la evidencia para el manejo integral de la DA en Colombia, considerando las necesidades específicas de adultos y niños. Se alienta a los profesionales de la salud a utilizar estas recomendaciones para optimizar la atención del paciente y mejorar los resultados clínicos.
- 13 December 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Open AccessDiagnóstico y tratamiento de la dermatitis atópica en Colombia. Actualización de la guía de práctica clínica
Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel altamente prevalente que afecta de manera negativa la calidad de vida de los pacientes y puede asociarse con comorbilidades sistémicas y afectación psicosocial. Se requiere la actualización de las guías de diagnóstico y tratamiento adecuado de la población y del contexto sanitario local. Objetivo: Esta actualización de la guía de práctica clínica (GPC), de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma), proporciona recomendaciones basadas en la evidencia para la evaluación y el manejo de la DA en Colombia, con un enfoque específico en tratamientos sistémicos, tópicos y terapias coadyuvantes, así como la gravedad y la gestión del riesgo. Estas recomendaciones están dirigidas a profesionales de la salud, tomadores de decisiones y pacientes. Métodos: Para desarrollar esta guía, se conformó un panel multidisciplinario de expertos y se llevó a cabo un proceso riguroso de revisión sistemática de la literatura para responder preguntas clínicas específicas. La certeza en la evidencia y la fuerza de las recomendaciones se evaluaron utilizando el enfoque GRADE (Grading of Recommendations Assessment, Development and Evaluation, por sus siglas en inglés). Resultados: El panel de expertos alcanzó consenso en once recomendaciones y nueve puntos de buena práctica para la atención de personas con DA. La revisión de la evidencia destaca la eficacia de crisaborol tópico, dupilumab, abrocitinib y upadacitinib en el manejo de la DA, con recomendaciones específicas para su uso en diferentes poblaciones. Se incluyen además recomendaciones para la descolonización de reservorios, la inmunoterapia con alérgenos y la restricción alimentaria, así como para la gestión del riesgo en el uso de terapias biológicas e inhibidores de las janocinasas (JAK, por sus siglas en inglés). Conclusiones: Esta guía proporciona recomendaciones actualizadas y basadas en la evidencia para el manejo integral de la DA en Colombia, considerando las necesidades específicas de adultos y niños. Se alienta a los profesionales de la salud a utilizar estas recomendaciones para optimizar la atención del paciente y mejorar los resultados clínicos.
- Open Access
- 29 August 2024
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 44 (3) , 318-327
Correlation between disease severity indices and quality of life measurement tools in atopic dermatitis patients
Introduction. Reports regarding the correlation and effect size of change of the full spectrum of quality of life and disease severity measures applied in-person to patients with atopic dermatitis are scarce.Objectives. To assess quality-of-life with 3 different instruments and to evaluate disease severity indices and to determine their correlation and effect size of change between two measurements.Materials and methods. Patient-level data were obtained through two in-person visits. Sociodemographic information and data related to disease distribution, severity (through the BSA, EASI, SCORAD, POEM, and itching scales), and the impact of atopic dermatitis on quality of life using the DLQI and Skindex-29, and EQ-5D, were assessed. The correlation between change in quality-of-life scores and disease severity scores in addition to the standardized effect size were also evaluated.Results. Only 139 out of 212 patients completed the follow-up visit. BSA highly correlated with SCORAD and EASI, and the lowest correlation was found with POEM. The best correlation of pruritus VAS was found with sleep disturbance. The SCORAD score highly correlated with EASI, and the lowest correlation was found with POEM. The magnitude of the effect at initiation of the study vs follow-up was in average moderate to important. Conclusions. Patients with atopic dermatitis experience a substantial burden on quality of life. Disease activity correlates better with quality-of-life measurements when the disease is less severe after starting therapy. POEM and Skindex-29 seem to be optimal to determine disease severity and quality of life in adults with atopic dermatitis.
- 29 August 2024
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 44 (3) , 318-327
Open AccessCorrelation between disease severity indices and quality of life measurement tools in atopic dermatitis patients
Introduction. Reports regarding the correlation and effect size of change of the full spectrum of quality of life and disease severity measures applied in-person to patients with atopic dermatitis are scarce.Objectives. To assess quality-of-life with 3 different instruments and to evaluate disease severity indices and to determine their correlation and effect size of change between two measurements.Materials and methods. Patient-level data were obtained through two in-person visits. Sociodemographic information and data related to disease distribution, severity (through the BSA, EASI, SCORAD, POEM, and itching scales), and the impact of atopic dermatitis on quality of life using the DLQI and Skindex-29, and EQ-5D, were assessed. The correlation between change in quality-of-life scores and disease severity scores in addition to the standardized effect size were also evaluated.Results. Only 139 out of 212 patients completed the follow-up visit. BSA highly correlated with SCORAD and EASI, and the lowest correlation was found with POEM. The best correlation of pruritus VAS was found with sleep disturbance. The SCORAD score highly correlated with EASI, and the lowest correlation was found with POEM. The magnitude of the effect at initiation of the study vs follow-up was in average moderate to important. Conclusions. Patients with atopic dermatitis experience a substantial burden on quality of life. Disease activity correlates better with quality-of-life measurements when the disease is less severe after starting therapy. POEM and Skindex-29 seem to be optimal to determine disease severity and quality of life in adults with atopic dermatitis.
- 13 September 2022
- Published by Medwave Estudios Limitada in Medwave
- Vol. 22 (08) , e002564
Epidemiologic characteristics and burden of psoriasis: A multicenter, cross-sectional study
Background Although psoriasis burden and treatment have been well characterized in developed countries, there are scarce in-depth epidemiological studies in Latin American countries. Objectives To describe the sociodemographic and clinical features and the economic burden of psoriasis among children and adult patients from Colombia. Methods This cross-sectional study included patients from dermatology private practice offices, health provider institutions and hospitals in seven Colombian cities. We collected data on disease distribution, weight, height, body mass index, waist-hip ratio, disease severity, therapy, personal history of comorbidities, and direct costs. Multiple logistic regression analyses were conducted to assess the associations between severity scales and sociodemographic and clinical variables. Results Two-hundred-three patients (43.8% women, 56.2% men) with an age range between 7 to 89 years old were included. The main subtype was psoriasis vulgaris and mean age of diagnosis was 37.1 years. The most common comorbidities were obesity, hypertension, psoriatic arthritis, dyslipidemia and diabetes. Women had a significant increased odds of presenting with psoriatic arthritis. Body-mass-index and hypertension were significantly associated with a higher psoriasis severity, whereas being female and non-obese was associated with a lower risk. A third of the patients had a family history of psoriasis and sleeping disorders. Forty-one percent of participants either had no income or had an income below 224 US dollars per month and >20% of their income was spent on their disease. Conclusions This study is supported by robust scientific data and contributes to understanding the burden of psoriasis in Latin America. This study adds well-supported data through an in-depth clinical and economical characterization of Colombian children and adult patients with psoriasis and shows the high impact and burden of the disease on patients and their families.
- 13 September 2022
- Published by Medwave Estudios Limitada in Medwave
- Vol. 22 (08) , e002564
Epidemiologic characteristics and burden of psoriasis: A multicenter, cross-sectional study
Background Although psoriasis burden and treatment have been well characterized in developed countries, there are scarce in-depth epidemiological studies in Latin American countries. Objectives To describe the sociodemographic and clinical features and the economic burden of psoriasis among children and adult patients from Colombia. Methods This cross-sectional study included patients from dermatology private practice offices, health provider institutions and hospitals in seven Colombian cities. We collected data on disease distribution, weight, height, body mass index, waist-hip ratio, disease severity, therapy, personal history of comorbidities, and direct costs. Multiple logistic regression analyses were conducted to assess the associations between severity scales and sociodemographic and clinical variables. Results Two-hundred-three patients (43.8% women, 56.2% men) with an age range between 7 to 89 years old were included. The main subtype was psoriasis vulgaris and mean age of diagnosis was 37.1 years. The most common comorbidities were obesity, hypertension, psoriatic arthritis, dyslipidemia and diabetes. Women had a significant increased odds of presenting with psoriatic arthritis. Body-mass-index and hypertension were significantly associated with a higher psoriasis severity, whereas being female and non-obese was associated with a lower risk. A third of the patients had a family history of psoriasis and sleeping disorders. Forty-one percent of participants either had no income or had an income below 224 US dollars per month and >20% of their income was spent on their disease. Conclusions This study is supported by robust scientific data and contributes to understanding the burden of psoriasis in Latin America. This study adds well-supported data through an in-depth clinical and economical characterization of Colombian children and adult patients with psoriasis and shows the high impact and burden of the disease on patients and their families.
- Open Access
- 1 November 2021
- Published by Universidad Nacional de Colombia in Revista de Salud Pública
- Vol. 23 (6) , 1-8
Hallazgos en piel en pacientes con infección por VIH en Bogotá
Objetivo Describir los hallazgos en piel y las características sociodemográficas de pacientes VIH positivos atendidos en un centro de remisión en Bogotá. Métodos Se realizó un estudio observacional descriptivo, incluyendo adultos con infección por VIH atendidos en el Hospital Universitario San Ignacio de Bogotá, entre abril de 2019 y febrero de 2020. A partir de un interrogatorio, un examen físico y la revisión de historias clínicas, se registraron hallazgos en piel, datos de terapia antirre- troviral recibida, conteo de linfocitos CD4+ y carga viral para VIH, así como pruebasmicológicas e histopatológicas (cuando fueron necesarias). Resultados Se evaluó un total de 168 pacientes que, en su mayoría, eran hombres (88,7%), en la cuarta década de la vida, de orientación HSH (77,4%), con fototipos del II al IV (97%) y manejados con terapia antirretroviral (94,6%). Se encontraron hallazgos en piel en el 97,6% de los pacientes, siendo más frecuentes las infecciones (43,8%), específicamente los condilomas anogenitales, principalmente en pacientes con 200 linfocitos CD4+/mm3. Conclusiones Los hallazgos más frecuentes en piel fueron: dermatitis seborreica, condilomas anogenitales, verrugas virales, moluscos contagiosos y micosis superficiales, que se asemeja a lo reportado en poblaciones con buen control inmunovirológico de la enfermedad. La alta prevalencia de condilomas anogenitales nos invita a imple- mentar estrategias de tamización para VPH, así como de educación en infecciones de transmisión sexual.
- 1 November 2021
- Published by Universidad Nacional de Colombia in Revista de Salud Pública
- Vol. 23 (6) , 1-8
Open AccessHallazgos en piel en pacientes con infección por VIH en Bogotá
Objetivo Describir los hallazgos en piel y las características sociodemográficas de pacientes VIH positivos atendidos en un centro de remisión en Bogotá. Métodos Se realizó un estudio observacional descriptivo, incluyendo adultos con infección por VIH atendidos en el Hospital Universitario San Ignacio de Bogotá, entre abril de 2019 y febrero de 2020. A partir de un interrogatorio, un examen físico y la revisión de historias clínicas, se registraron hallazgos en piel, datos de terapia antirre- troviral recibida, conteo de linfocitos CD4+ y carga viral para VIH, así como pruebasmicológicas e histopatológicas (cuando fueron necesarias). Resultados Se evaluó un total de 168 pacientes que, en su mayoría, eran hombres (88,7%), en la cuarta década de la vida, de orientación HSH (77,4%), con fototipos del II al IV (97%) y manejados con terapia antirretroviral (94,6%). Se encontraron hallazgos en piel en el 97,6% de los pacientes, siendo más frecuentes las infecciones (43,8%), específicamente los condilomas anogenitales, principalmente en pacientes con 200 linfocitos CD4+/mm3. Conclusiones Los hallazgos más frecuentes en piel fueron: dermatitis seborreica, condilomas anogenitales, verrugas virales, moluscos contagiosos y micosis superficiales, que se asemeja a lo reportado en poblaciones con buen control inmunovirológico de la enfermedad. La alta prevalencia de condilomas anogenitales nos invita a imple- mentar estrategias de tamización para VPH, así como de educación en infecciones de transmisión sexual.
- Open Access
- 1 January 2016
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (1) , 37-40
Inflammatory myofibroblastic tumor presenting as paraneoplastic pemphigus in a 7-year-old girl
- 1 January 2016
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (1) , 37-40
Open AccessInflammatory myofibroblastic tumor presenting as paraneoplastic pemphigus in a 7-year-old girl